Endomorphins fully activate a cloned human mu opioid receptor  by Gong, Jianhua et al.
Endomorphins fully activate a cloned human mu opioid receptor
Jianhua Gonga, Judith A. Stronga, Shengwen Zhanga, Xia Yuea, Robert N. DeHavenc,
Je¡rey D. Daubertc, Joel A. Casselc, Guangling Yuc, Erik Manssonc, Lei Yua;b;*
aDepartment of Cell Biology, Neurobiology and Anatomy,University of Cincinnati College of Medicine, 231 Bethesda Avenue, Cincinnati,
OH 45267-0521, USA
bDepartment of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0521, USA
cAdolor Corporation, Malvern, PA 19355, USA
Received 17 August 1998; received in revised form 6 October 1998
Abstract Endomorphins were recently identified as endogenous
ligands with high selectivity for mu opioid receptors. We have
characterized the ability of endomorphins to bind to and
functionally activate the cloned human mu opioid receptor. Both
endomorphin-1 and endomorphin-2 exhibited binding selectivity
for the mu opioid receptor over the delta and kappa opioid
receptors. Both agonists inhibited forskolin-stimulated increase
of cAMP in a dose-dependent fashion. When the mu opioid
receptor was coexpressed in Xenopus oocytes with G protein-
activated K+ channels, application of either endomorphin
activated an inward K+ current. This activation was dose-
dependent and blocked by naloxone. Both endomorphins acted as
full agonists with efficacy similar to that of [D-Ala2,N-Me-
Phe4,Gly-ol5]enkephalin (DAMGO). These data indicate that
endomorphins act as full agonists at the human mu opioid
receptor, capable of stimulating the receptor to inhibit the
cAMP/adenylyl cyclase pathway and activate G-protein-acti-
vated inwardly rectifying potassium (GIRK) channels.
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1. Introduction
Opioids, including both endogenous peptides and exoge-
nous alkaloids, exert their physiological e¡ects by interacting
with membrane-bound opioid receptors. These e¡ects include
regulation of pain perception, reinforcement and reward, neu-
rotransmitter release, hormone secretion, gastrointestinal mo-
tility, and respiratory activity [1]. Pharmacological studies
have identi¢ed three major types of opioid receptors in the
brain and spinal cord: mu, delta, and kappa, of which the mu
opioid receptor plays an important role in opioid analgesia
and development of opioid dependence [2,3]. Extensive studies
have also led to the identi¢cation of three major classes of
endogenous ligands in the mammalian brain: endorphins, en-
kephalins, and dynorphins [4]. Endorphins and enkephalins
can activate both the mu and delta opioid receptors, while
dynorphins are considered to be relatively selective for the
kappa opioid receptor.
Zadina et al. [5] isolated two endogenous opioid peptides
from the mammalian brain, named endomorphin-1 (Tyr-Pro-
Trp-Phe-NH2) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH2),
that display high a⁄nity and selectivity for the mu opioid
receptor. Endomorphin-1 was also demonstrated to have
higher binding a⁄nity than the synthetic mu-selective ana-
logue [D-Ala2,N-Me-Phe4,Gly-ol5]enkephalin (DAMGO) in
vitro, and to produce potent and prolonged analgesia in
mice [5]. However, these studies were conducted in brain tis-
sues and in vivo, in which multiple types of opioid receptors
are present.
The major cellular e¡ects of activation of all three types of
opioid receptors by their agonists are inhibition of adenylyl
cyclase and modulation of membrane Ca2 and K conduct-
ances [6,7]. Opioid-mediated increases in K conductance and
decrease in Ca2 conductance both serve to reduce membrane
excitability and contribute to the analgesic properties of the
opioids. Because cAMP is an important second messenger in
cell signalling, opioid inhibition of adenylyl cyclase implies a
more complex pathway for opioid regulation of cellular
mechanisms. These two major cellular e¡ects of mu opioid
receptor activation have been studied by using cloned mu
opioid receptors since expression of the cloned receptor pro-
vides a cellular model with a single de¢ned receptor type [8^
10]. In this study, we evaluated the functional e¡ects, includ-
ing both e⁄cacy and potency, of endomorphins on the cloned
human mu opioid receptor.
2. Materials and methods
2.1. Receptor expression and binding assay
Chinese hamster ovary (CHO) cells transfected with receptor
cDNAs in pcDNA3 (Invitrogen) using the calcium phosphate method
[11] and expressing the human mu (hMOR), delta (hDOR), or kappa
(hKOR) receptor [12] were used in this study. When 90% con£uence
was reached, the cells were scraped from the plates and were harvested
by centrifugation at 1000Ug for 10 min at 4‡C. The cell pellets were
then washed once and resuspended in ice-cold binding assay bu¡er
containing 50 mM Tris-HCl (pH 7.8), 1 mM EGTA, 5 mM MgCl2,
10 Wg/ml leupeptin, 10 Wg/ml pepstatin, 200 Wg/ml bacitracin, and
0.5 Wg/ml aprotinin, and homogenized using a Polytron homogenizer
(Brinkmann). The homogenates were centrifuged at 48 000Ug for
20 min at 4‡C to recover the membrane fractions. For the binding
assay, a membrane sample (50^100 Wg protein) was mixed with a
radio-labelled ligand ([3H]DAMGO or [3H]diprenorphine, Amersham
Life Science) and a test compound in a ¢nal volume of 500 Wl of the
assay bu¡er in 96-well deep-well polystyrene titer plates (Beckman).
The ¢nal concentration of [3H]DAMGO or [3H]diprenorphine after
mixing was 1 nM. Following incubation at 22‡C for 60 min, binding
was terminated by vacuum ¢ltration with a Brandel MPXR-96T Har-
vester through GF/B ¢lters that had been pretreated with a solution of
0.5% (w/v) polyethyleneimine and 0.1% (w/v) bovine serum albumin.
The ¢lter-bottom plates were washed four times with 1 ml each of ice-
cold 50 mM Tris-HCl (pH 7.8). Radioactivity on the ¢lters was then
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determined by scintillation spectrometry in a Packard TopCount in
Microscint-20 (Packard Instruments, Meriden, CT, USA). Binding
data were analyzed by non-linear regression using the GraphPad
Prism software program. The Ki values were calculated from IC50
by the Cheng-Pruso¡ equation [13] using the Kd values of
[3H]DAMGO and [3H]diprenorphine (4.1 nM for DAMGO binding
to the mu opioid receptor and 0.33 nM for diprenorphine binding to
the delta receptor).
Preliminary experiments were performed to show that no speci¢c
binding was lost during the wash of the ¢lters, that binding was at
equilibrium by 60 min and remained at equilibrium for at least an
additional 60 min, and that the binding was within the linear range
with regard to the protein amounts used for the assay. Non-speci¢c
binding, determined in the presence of 10 WM unlabeled naloxone,
was approximately 10% of total binding.
2.2. cAMP assay
CHO cells stably transfected with hMOR were seeded in 24-well
plates at the density of 5U104 cells/well. After incubation at 37‡C to
reach 90% con£uence in a F-12 Nutrient Mixture (HAM, Gibco-
BRL) supplemented with 1 mM glutamine, 10% (v/v) fetal calf serum,
100 Wg/ml each of penicillin and streptomycin, and 500 Wg/ml geneti-
cin, the cells were incubated in 0.5 ml of F-12 containing 500 WM of
isobutylmethylxanthine (IBMX) at 37‡C for 15 min prior to the treat-
ment with 500 WM IBMX, 25 WM forskolin, and agonists at appro-
priate concentrations in 0.5 ml of F-12 at 37‡C for 20 min. The
reactions were terminated by adding 0.1 ml of luciferase cell culture
lysis reagent (Promega) in 0.1 M HCl after removal of F-12. Aliquots
were removed and the concentrations of cAMP were determined using
the radioimmunoassay kit (NEN-DuPont) according to the manufac-
turer’s instructions. The data were analyzed by non-linear regression
using the GraphPad Prism software program.
2.3. Oocyte expression and electrophysiology
Xenopus oocytes were isolated using standard methods [14]. Syn-
thetic mRNAs for the human mu opioid receptor [9] and the G-pro-
tein-activated inwardly rectifying K channels, GIRK1 [15,16] and
GIRK2 [17,18], were transcribed in vitro, as described [8]. Thirty-
two nl of the mRNA solution (1 ng of the mu receptor mRNA and
0.5 ng each of GIRK1 and GIRK2 mRNAs) was injected into each
mature (stage V^VI) oocyte using a Drummond automatic microin-
jector. The injected oocytes were incubated in 50% (v/v) L-15 medium
supplemented with 0.8 mM glutamine and 10 Wg/ml gentamycin at
20‡C. Two to three days after injection, oocytes were voltage-clamped
at 380 mV using a two-microelectrode voltage clamp, the Axoclamp-
2A (Axon Instruments) under the control of pCLAMP software
(Axon Instruments). The electrodes were ¢lled with 3 M KCl and
had tip resistance of 0.5^3.0 M6. During recording, oocytes were
superfused with either ND96 (96 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2, and 5 mM HEPES, pH 7.5), a high K
solution (HK: 96 mM KCl, 2 mM NaCl, 1 mM MgCl2, 1.8 mM
CaCl2, and 5 mM HEPES, pH 7.5), or HK containing agonists.
The data were analyzed with the Microcal Origin software program.
3. Results
3.1. Binding of endomorphins to human opioid receptors
Zadina et al. [5] showed that in rodent brain homogenates,
endomorphins bind selectively to mu opioid receptors. To
determine the binding selectivity of endomorphins for the
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Table 1
Binding a⁄nity values of endomorphins to human mu, delta, and kappa opioid receptors
Ki (nM)
Mu Delta Kappa
Endomorphin-1 5.5 þ 0.4 824.3 þ 362.9 s 10 000
Endomorphin-2 8.1 þ 1.7 s 10 000 s 10 000
Summary of the data from three or more separate experiments. The results are presented as mean þ standard error. The Ki values of endomorphins
for the mu opioid receptor were determined by displacing [3H]DAMGO bound to the receptor, while the Ki values for delta and kappa receptors
were estimated by displacement of bound [3H]diprenorphine.
Fig. 1. Inhibition of forskolin-stimulated cyclic AMP increase by en-
domorphins and DAMGO. CHO cells stably transfected with the
human mu opioid receptor were treated with 25 WM forskolin in
the presence or absence of endomorphins or DAMGO at various
concentrations from 0.25 nM to 10 WM. The data for each point
were from three determinations of a representative experiment.
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cloned human opioid receptors, we used CHO cells trans-
fected with the human mu, delta, and kappa opioid receptor
clones for binding studies. Binding a⁄nity values of endomor-
phins for the human mu, delta, and kappa opioid receptors
are shown in Table 1. Both endomorphins exhibited high
a⁄nity and selectivity for the human mu opioid receptor,
with little or no binding for the delta or kappa opioid recep-
tors. The estimated Ki value of endomorphin-1 for the human
mu opioid receptor is 5.5 nM, an a⁄nity 150-fold higher than
that for the delta opioid receptor and over 1500-fold higher
than that for the kappa opioid receptor, indicating its selec-
tivity for the mu opioid receptor. Similarly, endomorphin-2
has a Ki value of 8.1 nM for the mu opioid receptor with very
little binding to the delta or kappa opioid receptors.
3.2. Inhibition of forskolin-stimulated cyclic AMP increase
Opioid receptors, including the mu opioid receptor, have
been shown to inhibit adenylyl cyclase activity and thus re-
duce the intracellular cAMP content [6]. To examine the func-
tional e¡ect of endomorphins on the cloned human mu opioid
receptor, the potency with which endomorphins inhibit the
increase of cAMP stimulated by forskolin was determined.
As shown in Fig. 1, endomorphins 1 and 2 have IC50 values
of 36.2 and 34.5 nM, respectively, and DAMGO has an IC50
value of 87.1 nM. These data indicate that both endomor-
phins, like DAMGO, can exert an inhibitory e¡ect on the
cAMP/adenylyl cyclase pathway via the cloned human mu
opioid receptor. The maximum inhibition of the cAMP in-
crease achieved in our experiments was 58% for endomor-
phin-1 (95% con¢dence level 49^66%), 65% for endomor-
phin-2 (95% con¢dence level 56^73%), and 55% for
DAMGO (95% con¢dence level 49^61%). There were no sig-
ni¢cant di¡erences between these values. Thus, comparable
levels of maximum cAMP inhibition between endomorphins
and DAMGO indicate that endomorphins are of similar e⁄-
cacy as DAMGO.
3.3. Activation of the mu opioid receptor coupled to
G-protein-activated K+ channels
The mu opioid receptor has been shown to activate cloned
G-protein-activated K channels in Xenopus oocytes upon
activation by its agonists, such as DAMGO [8,9,18]. To ex-
amine whether endomorphins can activate the mu opioid re-
ceptor in this functional assay, hMOR, GIRK1 and GIRK2
were coexpressed in oocytes, and the functional coupling of
the receptor to the K channels was assessed by two-electrode
voltage clamp. When the receptor was activated by superfus-
ing the oocytes with either of the endomorphins, an inward
current was observed (Fig. 2). This K current was induced
by activation of the expressed receptor, since it was com-
pletely blocked by the opioid receptor antagonist naloxone
(Fig. 2). Both endomorphins induced maximum K currents
comparable to those induced by the full agonist DAMGO
(Fig. 3), indicating that both endomorphins are full agonists
at the mu opioid receptor in this functional assay.
To examine the potency of endomorphins in activating the
mu opioid receptor, the dose e¡ects of endomorphins were
determined. Because of the variability of individual oocytes
in expressing exogenous proteins, we standardized the recep-
tor-mediated response by taking the ratio of the test agonist-
evoked current (Itest) at a particular dose to the maximum
current induced by DAMGO at a saturating concentration
(100 nM), as indicated in Fig. 4A. The activation of the mu
opioid receptor by endomorphins is dose dependent within the
range from 0.1 nM to 50 nM (Fig. 4B). The EC50 values
calculated from the dose response curves are 4.6 nM for en-
domorphin-1, 9.7 nM for endomorphin-2, and 14.0 nM for
DAMGO. These data demonstrate that both endomorphins
can fully induce the functional coupling between the mu
opioid receptor and G-protein-activated K channels with
similar e⁄cacy and potency to DAMGO.
4. Discussion
Activation of the mu opioid receptor by its agonists has two
major cellular e¡ects. One is the inhibitory e¡ect on the
cAMP/adenylyl cyclase pathway, resulting in reduced levels
of intracellular cAMP [6,19,20], an important second messen-
ger in cell signalling. The other is the modulation of ion
channels, such as increasing K conductance or decreasing
Ca2 conductance, to reduce cellular excitability [8,9,21^24].
In this study, we were interested in whether endomorphin-1
and endomorphin-2, two recently discovered endogenous pep-
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Fig. 2. Example of endomorphin-evoked K current mediated by
the human mu opioid receptor. Two representative endomorphin-
evoked current traces at a holding potential at 380 mV are shown.
Following superfusion with HK, the oocytes were perfused with HK
containing endomorphin-1 (100 nM) alone or followed by endomor-
phin-1 (100 nM) plus naloxone (10 WM), as indicated by the bars
above the current traces.
Fig. 3. E⁄cacy of endomorphins and DAMGO in activation of an
inwardly rectifying K current mediated by the human mu opioid
receptor. Data in panels A and B were from two di¡erent experi-
ments, presented as mean þ S.E. The concentration of endomorphin-
1 and DAMGO was 50 or 100 nM in panel A, and 50 nM in panel
B. A: The K current evoked by endomorphin-1 or DAMGO.
Endomorphin-1: 921 þ 49 nA, n = 9; DAMGO: 868 þ 43 nA, n = 9.
B: The K current evoked by endomorphin-2 or DAMGO. Endo-
morphin-2: 745 þ 77 nA, n = 5; DAMGO: 742 þ 82 nA, n = 5.
J. Gong et al./FEBS Letters 439 (1998) 152^156154
tides with high a⁄nity and selectivity for the mu opioid re-
ceptor [5], can activate the human mu opioid receptor to exert
these two major cellular e¡ects. Our binding data demon-
strated that both endomorphins bound to the mu opioid re-
ceptor with a⁄nity values comparable to that with the high
a⁄nity agonist DAMGO, and both endomorphins were
highly selective for the human mu opioid receptor over the
delta and kappa opioid receptors (Table 1). These observa-
tions are consistent with those reported by Zadina et al. [5] in
rodent brain tissues which contain several types of opioid
receptors.
The e¡ect of agonists on activation of opioid receptors and
their potency and e⁄cacy in the activation can be determined
in functional assays, as activation of mu opioid receptors by
agonists results in reduction in intracellular levels of cAMP
and in activation of co-expressed K channels in Xenopus
oocytes to produce an inward current [25]. In this study,
both endomorphins were shown to reduce the intracellular
level of cAMP and to evoke an inward K current with
high potency by activation of the cloned human mu opioid
receptor (Figs. 1, 3 and 4B), supporting the initial observation
in functional assays by Zadina et al. [5] using the guinea-pig
ileum system.
During the preparation of this report, two separate studies
published in which endomorphins were compared with DAM-
GO using mu opioid receptor-stimulated [35S]GTPQS binding
as the assay [26,27]. Based on this assay, the authors reported
that endomorphins are partial agonists at the mu opioid re-
ceptor. The mu opioid receptor similar to other G protein-
coupled receptors, achieves its cellular activity by ¢rst activat-
ing G proteins. Thus, receptor-stimulated [35S]GTPQS binding
serves as a valuable marker to indicate the ability of an ago-
nist to activate the receptor qualitatively. Whether the extent
of [35S]GTPQS binding parallels the e⁄cacy of an agonist
quantitatively remains to be established. In this context, it is
interesting to speculate on the di¡erence between the outcome
of these two studies and that in this report. We examined the
major cellular functions of the mu opioid receptor: inhibition
of cAMP synthesis and activation of K channels. In both
functional assays, the endomorphins showed full agonist ac-
tivity as compared with DAMGO, a well-recognized full ago-
nist at the mu opioid receptor. One explanation for the di¡er-
ent conclusions from our study and those by Sim et al. [26]
and Hosohata et al. [27] is that, while endomorphins may not
stimulate [35S]GTPQS binding to the same extent as that by
DAMGO, the amount of activated G protein is su⁄cient for a
full-scale cellular e¡ect.
In summary, this study showed that endomorphins are se-
lective full agonists for the cloned human mu opioid receptor,
capable of conferring high a⁄nity binding and e⁄cacious ac-
tivation of the human mu opioid receptor. Thus, the discovery
of endomorphins by Zadina et al. [5] opens the door to fur-
ther exploration of the physiological roles of these endoge-
nous peptides.
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